While conventional antibody binds to target antigen in both tumor and normal tissues. Switch-Ig® enables binding of antibody to target antigen only within tumor environment, and enables more effective and safer antibody therapeutics in cancer immunotherapy. This is achieved by our proprietary antibody engineering technology that allows antibody to only bind to the target antigen in the presence of extracellular adenosine triphosphate which is abundantly present in tumor microenvironment. Our first Switch Antibody™, STA551, is now being tested in clinical study, and we have multiple Switch Antibody™ projects in the drug discovery stage.
Antibody to CD137 activated by extracellular adenosine triphosphate is tumor selective and broadly effective in vivo without systemic immune activation
Cancer Discovery, Published Online First August 25, 2020